[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342563-105":59,"doc-detail-342563-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gene-therapy-in-glioblastoma-multiforme-can-it-be-a-role-changer-review-article","Gene therapy in glioblastoma multiforme: Can it be a role changer? - Review article","","Glioblastoma multiforme (GBM) remains one of the most lethal brain cancers, with poor survival and limited progress in effective therapies. Standard-of-care surgery, radiotherapy, and temozolomide have not substantially improved overall or progression-free survival, largely due to tumor heterogeneity and major delivery barriers such as the blood-brain barrier and tumor-blood (brain-tumor) barrier. Targeted approaches like mAbs and small molecules have also shown limited survival impact. This review outlines current status, advancements, and future prospects of gene therapy for GBM.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gene-therapy-in-glioblastoma-multiforme-can-it-be-a-role-changer-review-article/342563/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gene-therapy-in-glioblastoma-multiforme-can-it-be-a-role-changer-review-article/342563.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes GBM treatment especially difficult?","Question",{"text":112,"@type":113},"GBM shows strong resistance to conventional radiotherapy and chemotherapy, driven by complex genetic heterogeneity, invasive tumor behavior, and major drug-delivery barriers such as the blood-brain barrier and brain-tumor barrier.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What barriers limit therapeutic delivery in GBM?",{"text":117,"@type":113},"Drug delivery is constrained by the blood-brain barrier and the brain-tumor barrier, whose heterogeneous permeability creates hypoxic regions and supports drug resistance; both structures can also express P-glycoprotein to enhance drug efflux.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review position gene therapy for GBM?",{"text":121,"@type":113},"Gene therapy is presented as a promising advanced approach that may address limitations of prior and emerging therapies by leveraging its distinct properties, and the review summarizes current advancements and future prospects for GBM treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342563,1790128295,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Heliyon 10 (2024) e27087  \nContents lists available at ScienceDirect  \nHeliyon  \njournal [homepage:](homepage: www.cell.com/heliyon)[ www.cell.com/heliyon](homepage: www.cell.com/heliyon)  \n| Review article\u003Cbr>Gene therapy in glioblastoma multiforme: Can it be a role changer?\u003Cbr>*\u003Cbr>Mohammad Rayati , Vahid Mansouri , Naser Ahmadbeigi\u003Cbr>Gene Therapy Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Malignant glioma Glioblastoma Gene therapy Immunotherapy Viral vector GBM |  | Glioblastoma multiforme (GBM) is one of the most lethal cancers with a poor prognosis. Over the past century since its initial discovery and medical description, the development of effective treatments for this condition has seen limited progress. Despite numerous efforts, only a handful of drugs have gained approval for its treatment. However, these treatments have not yielded substantial improvements in both overall survival and progression-free survival rates. One reason for this is its unique features such as heterogeneity and difficulty of drug delivery because of two formidable barriers, namely the blood-brain barrier and the tumor-blood barrier. Over the past few years, significant developments in therapeutic approaches have given rise to promising novel and advanced therapies. Target-specific therapies, such as monoclonal antibodies (mAbs) and small molecules, stand as two important examples; however, they have not yielded a significant improvement in survival among GBM patients. Gene therapy, a relatively nascent advanced approach, holds promise as a potential treatment for cancer, particularly GBM. It possesses the potential to address the limitations of previous treatments and even newer advanced therapies like mAbs, owing to its distinct properties. This review aims to elucidate the current status and advancements in gene therapy for GBM treatment, while also presenting its future prospects. |\n\n1. Introduction  \nGlioblastoma multiforme (GBM) is a grade IV glioma originating from glial cells in the central nervous system (CNS). It accounts for 14.5% and 48.6% of all central nervous system tumors and malignant central nervous system tumors, respectively. Its incidence is approximately 0.85 per 100,000 in under 18 population and about 4 in 100,000 in adults [1]. It is one of the most complex and treatment-resistant cancers, with an estimated annual mortality rate of over 10,000 individuals in the United States. The five-year overall survival rate stands at less than 7%, and the mean survival time is estimated to be under one year, approximately 8 months. The situation has remained largely unchanged for decades. The current standard of care (SOC) involves surgical resection with a maximum safe margin, followed by radiation therapy (RT) and temozolomide (TMZ). Despite its description in scientific literature over a century ago, only five drugs (TMZ, lomustine, intravenous carmustine, carmustine wafer implants, and bevacizumab (BVZ)) and one device (tumor treatment fields (TTFields)) have received FDA approval. Remarkably, none of these interventions have achieved significant success in extending patient survival beyond a few months [2,3].  \n* Corresponding author. Gene Therapy Research Center, Digestive Diseases Research Institute, Shariati Hospital, North Karegar St, Tehran 1411713135, Iran.  \nE-mail address: [n-ahmadbeigi@sina.tums.ac.ir](n-ahmadbeigi@sina.tums.ac.ir) (N. Ahmadbeigi).  \n[https://doi.org/10.1016/j.heliyon.2024.e27087](https://doi.org/10.1016/j.heliyon.2024.e27087)  \nReceived 26 September 2023; Received in revised form 7 February 2024; Accepted 23 February 2024 Available online 24 February 2024  \n2405-8440/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http:","cbCaidCfdS60NgeY","https://ap.wps.com/l/cbCaidCfdS60NgeY","pdf",1817381,11,"English","# Introduction\n# Why GBM treatment is too difficult: treatment challenges\n# Innovative and advanced cancer treatments","[{\"question\":\"What makes GBM treatment especially difficult?\",\"answer\":\"GBM shows strong resistance to conventional radiotherapy and chemotherapy, driven by complex genetic heterogeneity, invasive tumor behavior, and major drug-delivery barriers such as the blood-brain barrier and brain-tumor barrier.\"},{\"question\":\"What barriers limit therapeutic delivery in GBM?\",\"answer\":\"Drug delivery is constrained by the blood-brain barrier and the brain-tumor barrier, whose heterogeneous permeability creates hypoxic regions and supports drug resistance; both structures can also express P-glycoprotein to enhance drug efflux.\"},{\"question\":\"How does the review position gene therapy for GBM?\",\"answer\":\"Gene therapy is presented as a promising advanced approach that may address limitations of prior and emerging therapies by leveraging its distinct properties, and the review summarizes current advancements and future prospects for GBM treatment.\"}]","Gene therapy in glioblastoma multiforme: Can it be a role changer? - Review article | PDF",1790047159,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d09c767cbac3356149dc3efdf936846.webp",983,1341,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2b41a56cd9a61309bb95b1b2f751097.webp",982,1340,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85bd86af020def70dac9a51f6f0d91b6.webp",981,1338,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0bc7ec6b359d2dc46f3c82bb8aa2a62.webp",980,1337]